PTEN status determines chemosensitivity to proteasome inhibition in cholangiocarcinoma-Reference-Cited by-同舟云学术

PTEN status determines chemosensitivity to proteasome inhibition in cholangiocarcinoma

Published:2020-09-23 Issue:562 Volume:12 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Jiang Tian-Yi¹²^ORCID,Pan Yu-Fei²³^ORCID,Wan Zheng-Hua²,Lin Yun-Kai¹²,Zhu Bin⁴^ORCID,Yuan Zhen-gang⁴^ORCID,Ma Yun-Han¹²^ORCID,Shi Yuan-Yuan¹,Zeng Tian-Mei⁴^ORCID,Dong Li-Wei¹³^ORCID,Tan Ye-Xiong²³^ORCID,Wang Hong-Yang¹²³⁵⁶^ORCID

Affiliation:

1. International Cooperation Laboratory on Signal Transduction, Eastern Hepatobiliary Surgery Institute, Second Military Medical University, Shanghai 200438, China.

2. National Center for Liver Cancer, Shanghai 201805, China.

3. Shanghai Key Laboratory of Hepato-biliary Tumor Biology, Shanghai 200438, China.

4. Department of Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai 200438, China.

5. State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200127, China.

6. Laboratory of Signaling Regulation and Targeting Therapy of Liver Cancer, Second Military Medical University & Ministry of Education, Shanghai 200438, China.

Abstract

PTEN loss promotes the expression of genes encoding proteasome subunits and facilitates bortezomib chemosensitivity.

Funder

the National Natural Science Foundation of China

The National Key Research and Development Program

the state Key project for liver cancer

the Funds for Creative Research Groups of China

the Precision Medicine Project of Second Military Medical University

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine